



# Biotechnology and Molecular Biology Reviews

Volume 9 Number 3, July 2014

ISSN 1538-2273



*Academic  
Journals*

## ABOUT BMBR

The **Biotechnology and Molecular Biology Reviews (BMBR)** (ISSN 1538-2273) is published Monthly (one volume per year) by Academic Journals.

**Biotechnology and Molecular Biology Reviews (BMBR)**, a new broad-based review journal, is an open access journal that was founded on two key tenets: (1) to publish the most exciting, cutting-edge reviews in all areas of applied biochemistry, industrial microbiology, genomics and proteomics, and metabolic engineering, and (2) to provide the most rapid turn-around time possible for reviewing and publishing. It is our hope these articles will serve teaching and reference tools.

## Submission of Manuscript

Please read the **Instructions for Authors** before submitting your manuscript. The manuscript files should be given the last name of the first author

[Click here to Submit manuscripts online](#)

If you have any difficulty using the online submission system, kindly submit via this email [bmb@academicjournals.org](mailto:bmb@academicjournals.org).

With questions or concerns, please contact the Editorial Office at [bmb@academicjournals.org](mailto:bmb@academicjournals.org).

## Editor-In-Chief

**P. Ravindra, Ph.D.**

*School of Engineering & IT  
University Malaysia Sabah  
88999, Kota Kinabalu, Sabah, Malaysia*

## Editor

**David Maina Menge, Ph.D.**

*University of California, Irvine  
College of Health Sciences/Program in Public Health  
Hewitt Hall Room 3501; Irvine, CA 92697-4050, USA.*

**Evans Kaimoyo, Ph.D.**

*Plant Microbe-interactions Laboratory,  
Boyce Thompson Institute of Plant Research,  
Ithaca, NY, 14853, USA.*

**Solomon Olawale Odemuyiwa, Ph.D.**

*Pulmonary Research Group  
Department of Medicine  
550 Heritage Medical Research Centre  
University of Alberta  
Edmonton  
Canada T6G 2S2*

**Vikash Kumar Dubey**

*Assistant Professor  
Department of Biotechnology  
Room No: 1N 102  
Indian Institute of Technology, Guwahati  
Guwahati- 781039, Assam,  
India.*

**Beng Ti Tey**

*Department of Chemical and Environmental  
Engineering,  
Faculty of Engineering,  
Universiti Putra,  
Malaysia*

**Behera B.C.**

*Agharkar Research Institute  
Pune-411004, India*

## Editorial Board

**Dr. Daiana P. Stolf**

*University of Toronto,  
Toronto,  
Canada*

**Dr. Stephane Chevaliez**

*Department of Virology and INSERM,  
Henri Mondor Hospital,  
avenue du Maréchal de Lattre de Tassigny  
Cretéil*

**Dr. Mohammad Asgharzadeh**

*Tuberculosis and Lung Disease Research  
Center and Biotechnology Research Center,  
Tabriz University of Medical Sciences,  
Iran*

**Dr. Mukul Das**

*Food Toxicology Division Industrial Toxicology Research  
Centre  
Mahatma Gandhi Marg Lucknow,  
India*

**Dr. Jian-Zhong Liu**

*Biotechnology Research Center,  
Zhongshan (Sun Yat-Sen) University Guangzhou,  
China*

**Prof. Peter J. Reilly**

*Dept of Chemical and Biological Eng  
Ansonlowa State University*

**Prof. Mohammad Miransari**

*Department of Soil Science,  
College of Agricultural Sciences,  
Shahed University,  
Tehran,  
Iran*

**Dr. Chhandak Basu**

*School of Biological Sciences  
Ross Hall University of Northern Colorado Greeley,  
Colorado  
USA*

**Prof. Anil Kumar**

*School of Biotechnology Devi Ahilya University,  
Khandwa Road,  
Indore,  
India*

**Dr. Ahmed M Malki**

*Alexandria University,  
Faculty of Science,  
Biochemistry department,  
Alexandria,  
Egypt*

**Dr. Christopher Brigham**

*Sinskey Laboratory  
Massachusetts Institute of Technology  
Cambridge,  
USA*

**Prof. Mahmoud Saker**

*National Research Center,  
El Behouse St., Dokki,  
Cairo,  
Egypt*

**Prof. Karl Bayer**

*Institute of Applied Microbiology,  
University of Natural Resources and Applied Life  
Sciences,  
Muthgasse  
Austria.*

**Dr. Hector Budman**

*University of Waterloo  
Waterloo,  
Ontario*

**Prof. Mohammad Miransari**

*Shahed University,  
Tehran,  
Iran*

**Prof. R.P Singh**

*University of Roorkee,  
Roorkee  
India*

**Prof. Jane B. Lian**

*University of Massachusetts Medical School 55  
Lake Avenue  
North Worcester*

**Dr. Vicki Ann Luna**

*University of South Florida  
USA*

**Dr. Helene F Rosenberg**

*National Institute of Allergy and Infectious Diseases  
Rockville Pike, Bethesda,  
USA*

**Dr. Silvia Bautista-Baños**

*National Polytechnic Institute Yautepec,  
Morelos Cuernavaca,  
México*

**Dr. RA Siddique**

*Department of Veterinary Biochemistry.  
College of Veterinary Science and Animal Husbandry.  
Navsari Agricultural University,  
Navsari Gujarat,  
India*

**Dr. Eijiro Miyak**

*Health Technology Research Center,  
National Institute of Advanced Industrial Science and  
Technology (AIST)  
Takamatsu,  
Japan*

**Dr. Carla Marchetti**

*Istituto di Biofisica.  
Consiglio Nazionale delle Ricerche.  
via De Marini, Genova,  
Italy*

**Dr. T Anjana Devi**

*Centre for Chemical Biology,  
Indian Institute of chemical technology  
Habsiguda Hyderabad  
Andhra Pradesh,  
India*

**Dr. Moytri Roy-Chowdhury**

*Washington State University-  
Pullman,  
Washington  
USA*

**Dr. Poluri Krishna Mohan**

*University of Texas  
Department of Biochemistry and Molecular Biology  
and The Sealy Center for Structural Biology and  
Molecular Biophysics  
Medical Branch Galveston,  
Texas*

**Dr. Gao Guo**

*School of Dentistry,  
University of California, Los Angeles (UCLA)  
10833 Le Conte Avenue  
Los Angeles, CA 90095,  
USA*

**Dr. Alireza Valdiani**

*Department of Biochemistry,  
Faculty of Biotechnology and Biomolecular  
Sciences,  
University Putra Malaysia,  
43400 UPM Serdang,  
Selangor DE,  
Malaysia*

**Dr. S. A. Anitha Christy**

*Genomic Medicine  
Methodist Hospital Research Institute  
8.330, Bertner Ave  
Houston, TX 77030*

**Dr. Sridhar Boppana**

*Department of Pediatrics,  
Center for Advanced Biotechnology  
and Medicine (CABM),  
University of Medicine and Dentistry  
of New Jersey (UMDNJ),  
679 Hoes Lane West, Piscataway,  
New Jersey- 08854.  
USA*

**Dr. Jeffy George**

*Department of Microbiology and Immunology  
F. Edward Hébert School of Medicine  
Uniformed Services University of the Health  
Sciences  
4301 Jones Bridge Road,  
Bethesda, MD 20814*

**Dr. Ajamaluddin Malik**

*Protein Research Chair  
Department of Biochemistry  
College of Science  
Building no 5, room no 2A46  
P.O. Box 2455  
King Saud University  
Riyadh 11451  
Kingdom of Saudi Arabia*

**Dr. Deepshikha Pande Katare**

*Amity Institute of Biotechnology, AUUP, Noida,  
India*

**Dr. Haopeng Wang**

*Arthur Weiss Lab  
UCSF-HHMI  
513 Parnassus Ave, S-1024 Bay3, BOX 0795,  
San Francisco, CA, 94143-0795*

**Dr. Mohammad Shoeb**

*University of Texas Medical  
Branch, Galveston-TX,  
USA*

**Dr. Bechan Sharma**

*Department of Biochemistry  
University of Allahabad,  
Allahabad, 211 002,  
India*

**Dr. Sarita Saraswati**

*Department of Pharmacology,  
College of Medicine,  
King Saud University, Riyadh  
Kingdom of Saudi Arabia*

**Dr. Santosh R. Mohanty**

*Soil Microbiology  
Department of Soil Biology  
Indian Institute of Soil Science,  
Indian Council of Agricultural Research (ICAR)  
Bearsia Road, Nabibagh, Bhopal, MP,  
India*

**Dr. Yule Yue Wang**

*Biotechnology and Medicinal Biochemistry  
Division of Life Science  
The Hong Kong University of Science & Technology  
Clear Water Bay,  
Hong Kong*

**Dr. Yogender Pal Khosa**

*Department of Microbiology,  
University of Delhi South Campus,  
New Delhi – 110021*

**Dr. Wei Li Cai**

*Eunice Kennedy Shriver National Institute of Child  
Health and Human Development  
National Institutes of Health,  
18 Library Drive, MSC-5430  
Bethesda, MD 20892*

**Dr. Alireza Valdiani**

*Department of Biochemistry,  
Faculty of Biotechnology and Biomolecular  
Sciences,  
Universiti Putra Malaysia (UPM),  
43400 UPM Serdang  
Malaysia*

# Instructions for Author

**Electronic submission** of manuscripts is strongly encouraged, provided that the text, tables, and figures are included in a single Microsoft Word file (preferably in Arial font).

The **cover letter** should include the corresponding author's full address and telephone/fax numbers and should be in an e-mail message sent to the Editor, with the file, whose name should begin with the first author's surname, as an attachment.

## Article Types

Three types of manuscripts may be submitted:

**Regular articles:** These should describe new and carefully confirmed findings, and experimental procedures should be given in sufficient detail for others to verify the work. The length of a full paper should be the minimum required to describe and interpret the work clearly.

**Short Communications:** A Short Communication is suitable for recording the results of complete small investigations or giving details of new models or hypotheses, innovative methods, techniques or apparatus. The style of main sections need not conform to that of full-length papers. Short communications are 2 to 4 printed pages (about 6 to 12 manuscript pages) in length.

**Reviews:** Submissions of reviews and perspectives covering topics of current interest are welcome and encouraged. Reviews should be concise and no longer than 4-6 printed pages (about 12 to 18 manuscript pages). Reviews are also peer-reviewed.

## Review Process

All manuscripts are reviewed by an editor and members of the Editorial Board or qualified outside reviewers. Authors cannot nominate reviewers. Only reviewers randomly selected from our database with specialization in the subject area will be contacted to evaluate the manuscripts. The process will be blind review.

Decisions will be made as rapidly as possible, and the journal strives to return reviewers' comments to authors as fast as possible. The editorial board will re-review manuscripts that are accepted pending revision. It is the goal of the AJFS to publish manuscripts within weeks after submission.

## Regular articles

All portions of the manuscript must be typed double-spaced and all pages numbered starting from the title page.

**The Title** should be a brief phrase describing the contents of the paper. The Title Page should include the authors' full names and affiliations, the name of the corresponding author along with phone, fax and E-mail information. Present addresses of authors should appear as a footnote.

**The Abstract** should be informative and completely self-explanatory, briefly present the topic, state the scope of the experiments, indicate significant data, and point out major findings and conclusions. The Abstract should be 100 to 200 words in length. Complete sentences, active verbs, and the third person should be used, and the abstract should be written in the past tense. Standard nomenclature should be used and abbreviations should be avoided. No literature should be cited.

Following the abstract, about 3 to 10 key words that will provide indexing references should be listed.

A list of non-standard **Abbreviations** should be added. In general, non-standard abbreviations should be used only when the full term is very long and used often. Each abbreviation should be spelled out and introduced in parentheses the first time it is used in the text. Only recommended SI units should be used. Authors should use the solidus presentation (mg/ml). Standard abbreviations (such as ATP and DNA) need not be defined.

**The Introduction** should provide a clear statement of the problem, the relevant literature on the subject, and the proposed approach or solution. It should be understandable to colleagues from a broad range of scientific disciplines.

**Materials and methods** should be complete enough to allow experiments to be reproduced. However, only truly new procedures should be described in detail; previously published procedures should be cited, and important modifications of published procedures should be mentioned briefly. Capitalize trade names and include the manufacturer's name and address. Subheadings should be used. Methods in general use need not be described in detail.

**Results** should be presented with clarity and precision. The results should be written in the past tense when describing findings in the authors' experiments. Previously published findings should be written in the present tense. Results should be explained, but largely without referring to the literature. Discussion, speculation and detailed interpretation of data should not be included in the Results but should be put into the Discussion section.

**The Discussion** should interpret the findings in view of the results obtained in this and in past studies on this topic. State the conclusions in a few sentences at the end of the paper. The Results and Discussion sections can include subheadings, and when appropriate, both sections can be combined.

**The Acknowledgments** of people, grants, funds, etc should be brief.

**Tables** should be kept to a minimum and be designed to be as simple as possible. Tables are to be typed double-spaced throughout, including headings and footnotes. Each table should be on a separate page, numbered consecutively in Arabic numerals and supplied with a heading and a legend. Tables should be self-explanatory without reference to the text. The details of the methods used in the experiments should preferably be described in the legend instead of in the text. The same data should not be presented in both table and graph form or repeated in the text.

**Figure legends** should be typed in numerical order on a separate sheet. Graphics should be prepared using applications capable of generating high resolution GIF, TIFF, JPEG or Powerpoint before pasting in the Microsoft Word manuscript file. Tables should be prepared in Microsoft Word. Use Arabic numerals to designate figures and upper case letters for their parts (Figure 1). Begin each legend with a title and include sufficient description so that the figure is understandable without reading the text of the manuscript. Information given in legends should not be repeated in the text.

**References:** In the text, a reference identified by means of an author's name should be followed by the date of the reference in parentheses. When there are more than two authors, only the first author's name should be mentioned, followed by 'et al'. In the event that an author cited has had two or more works published during the same year, the reference, both in the text and in the reference list, should be identified by a lower case letter like 'a' and 'b' after the date to distinguish the works.

Examples:

Abayomi (2000), Agindotan et al. (2003), (Kelebeni, 1983), (Usman and Smith, 1992), (Chege, 1998;

1987a,b; Tijani, 1993,1995), (Kumasi et al., 2001) References should be listed at the end of the paper in alphabetical order. Articles in preparation or articles submitted for publication, unpublished observations, personal communications, etc. should not be included in the reference list but should only be mentioned in the article text (e.g., A. Kingori, University of Nairobi, Kenya, personal communication). Journal names are abbreviated according to Chemical Abstracts. Authors are fully responsible for the accuracy of the references.

Examples:

Chikere CB, Omoni VT and Chikere BO (2008). Distribution of potential nosocomial pathogens in a hospital environment. *Afr. J. Biotechnol.* 7: 3535-3539.

Moran GJ, Amii RN, Abrahamian FM, Talan DA (2005). Methicillinresistant *Staphylococcus aureus* in community-acquired skin infections. *Emerg. Infect. Dis.* 11: 928-930.

Pitout JDD, Church DL, Gregson DB, Chow BL, McCracken M, Mulvey M, Laupland KB (2007). Molecular epidemiology of CTXM-producing *Escherichia coli* in the Calgary Health Region: emergence of CTX-M-15-producing isolates. *Antimicrob. Agents Chemother.* 51: 1281-1286.

Pelczar JR, Harley JP, Klein DA (1993). *Microbiology: Concepts and Applications.* McGraw-Hill Inc., New York, pp. 591-603.

### Short Communications

Short Communications are limited to a maximum of two figures and one table. They should present a complete study that is more limited in scope than is found in full-length papers. The items of manuscript preparation listed above apply to Short Communications with the following differences: (1) Abstracts are limited to 100 words; (2) instead of a separate Materials and Methods section, experimental procedures may be incorporated into Figure Legends and Table footnotes; (3) Results and Discussion should be combined into a single section.

Proofs and Reprints: Electronic proofs will be sent (e-mail attachment) to the corresponding author as a PDF file. Page proofs are considered to be the final version of the manuscript. With the exception of typographical or minor clerical errors, no changes will be made in the manuscript at the proof stage.



**Fees and Charges:** Authors are required to pay a \$550 handling fee. Publication of an article in the Biotechnology and Molecular Biology Reviews is not contingent upon the author's ability to pay the charges. Neither is acceptance to pay the handling fee a guarantee that the paper will be accepted for publication. Authors may still request (in advance) that the editorial office waive some of the handling fee under special circumstances

**Copyright: © 2014, Academic Journals.**

All rights Reserved. In accessing this journal, you agree that you will access the contents for your own personal use but not for any commercial use. Any use and or copies of this Journal in whole or in part must include the customary bibliographic citation, including author attribution, date and article title.

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, or thesis) that it is not under consideration for publication elsewhere; that if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher.

**Disclaimer of Warranties**

In no event shall Academic Journals be liable for any special, incidental, indirect, or consequential damages of any kind arising out of or in connection with the use of the articles or other material derived from the BMBR, whether or not advised of the possibility of damage, and on any theory of liability.

This publication is provided "as is" without warranty of any kind, either expressed or implied, including, but not limited to, the implied warranties of merchantability, fitness for a particular purpose, or non-infringement. Descriptions of, or references to, products or publications does not imply endorsement of that product or publication. While every effort is made by Academic Journals to see that no inaccurate or misleading data, opinion or statements appear in this publication, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Academic Journals makes no warranty of any kind, either express or implied, regarding the quality, accuracy, availability, or validity of the data or information in this publication or of any other publication to which it may be linked.

## **Biotechnology and Molecular Biology Reviews**

**Table of Contents: Volume 9 Number 3 July, 2014**

### **ARTICLES**

**Comparative analysis of different immunological techniques for diagnosing fasciolosis in sheep: A review**

Irfan-ur-Rauf Tak, Jehangir Shafi Dar, B. A. Ganai, M. Z. Chishti, R. A. Shahardar, Towsief Ahmad Tantry, Masarat Nizam and Shoaib Ali Dar

## Review

## Comparative analysis of different immunological techniques for diagnosing fasciolosis in sheep: A review

Irfan-ur-Rauf Tak<sup>1\*</sup>, Jehangir Shafi Dar<sup>1</sup>, B. A. Ganai<sup>1</sup>, M. Z. Chishti<sup>1</sup>, R. A. Shahardar<sup>2</sup>, Towsief Ahmad Tantry<sup>1</sup>, Masarat Nizam<sup>1</sup> and Shoaib Ali Dar<sup>3</sup>

<sup>1</sup>Centre of Research for Development, University of Kashmir, Srinagar-190 006, India.

<sup>2</sup>Department of Veterinary Parasitology, SKUAST, Kashmir, India.

<sup>3</sup>Department of Zoology, Punjabi University, Patiala, India.

Received 24 March, 2014; Accepted 9 June, 2014

Fasciolosis is a worldwide zoonotic infection caused by liver flukes of the genus *Fasciola*, of which *Fasciola hepatica* and a larger species, *Fasciola gigantica* are the most common representatives. These two food-borne trematodes usually infect domestic ruminants and cause important economic losses to sheep, goats and cattle. In commercial herds, fasciolosis is of great economic significance worldwide with losses estimated to exceed 2000 million dollars yearly, affecting more than 600 million animals, in articles reported a decade ago. In addition, *F. hepatica* causes an estimated loss of \$3 billion worldwide per annum through livestock mortality, especially in sheep, and by decreased productivity via reduction of milk and meat yields in cattle. The parasitological diagnosis of fasciolosis is often unreliable because the parasite's eggs are not found during the prepatent period. Even when the worms have matured, the diagnosis may still be difficult since eggs are only intermittently released. Repeated examinations of stools are usually required to increase the accuracy of the diagnosis. Early diagnosis of fasciolosis is necessary for institution of prompt treatment before irreparable damage of the liver occurs. For these reasons, serology is the most dependable method for diagnosing fasciolosis. Attempts have been made to diagnose fasciolosis by detecting antibodies in the serum of sheep suspected of being infected with the flukes. Advances in immunodiagnosis have focused on detection of *Fasciola* antigens in host body fluid; these tests have an advantage over antibody detection because antigenemia implies recent and active infection. Similarly, somatic and excretory secretory (E/S) antigens of *Fasciola* sp. or their partially purified component are the commonest source of antigens used in protection trials and serodiagnosis. Thus, the aim of the present review is to encourage more young researchers to initiate work on this aspect of these economically cosmopolitan parasites.

**Key words:** Fasciolosis, Antigenemia, E/S antigens, serodiagnosis, immunoassay, *Fasciola* spp., zoonotic disease.

### INTRODUCTION

Livestock infection by the liver flukes like *Fasciola hepatica* and *Fasciola gigantica* causes major economic

losses worldwide. Mostly, the infection by members of the genus *Fasciola*, commonly known as liver flukes, may be

responsible for morbidity and mortality in most mammal species, but have particular importance in sheep and cattle to livestock producers. Infection with *F. hepatica* and *F. gigantica* is regarded as one of the most common single helminth infection of ruminants in Asia and Africa (Hammond and Sewell, 1990). *Fasciola* spp. parasitizes a wide spectrum of domestic and wild animals (e.g., sheep, cattle, buffaloes and deer) and it causes a huge economic loss of \$3 billion annually to the agriculture sector worldwide through losses of milk and meat yields (Mas-Coma et al., 2005; Robinson and Dalton, 2009). The immature flukes after penetrating the liver capsule migrate into the liver hepatic tissue. This migration usually cause trauma with hemorrhages, necrosis and subsequent granulation end by liver cirrhosis (Ozer et al., 2003). It has been reported that sheep and cattle do not develop strong immunity to infection by *Fasciola* species, or to re-infections, and this lack of resistance in ruminants is believed to be associated with the inability of their macrophages to produce nitric oxide. The parasitological diagnosis of fasciolosis is often unreliable because the parasite eggs are not found during the prepatent period (Noureldin et al., 2004). Even when the worms have matured, the diagnosis may still be difficult since eggs are only intermittently released. Repeated examinations of stools are usually required to increase the accuracy of the diagnosis. Early diagnosis of liver fluke infection is necessary for institution of prompt treatment before irreparable damage of the liver occurs (Rokni et al., 2004). For these reasons, serology is the most dependable diagnostic method. Attempts have been made to diagnose fasciolosis by detecting antibodies in the serum patient suspected of being infected with the flukes (Maleewong et al., 1999). Advances in immuno-diagnosis have focused on detection of parasite antigens in host body fluid; these tests have an advantage over antibody detection because antigenemia implies recent and active infection (Cornelissen et al., 1999). The somatic and E/S antigens of *Fasciola* spp. or their partially purified component are the commonest source of antigens used in protection trials and serodiagnosis (G'nen et al., 2004). Immunodiagnosis of parasitic disease is mainly based on antibody detection (Fagbemi et al, 1999) and revealed both recent and current infections with early diagnosis. To obtain reliable diagnostic method or to identify crude antigens, many authors prepared antigens from whole worm (Hillyer et al., 1987) or from tegument (Charmy et al., 1997) also coproantigen (Allan et al., 1996), egg antigen (Khalil et al., 1989 and Abdel-Rahman and Abdel Mageed, 2000), and excretory secretory products (Espino et al., 1994). Currently, haemagglutination (HA), indirect fluorescence antibody test (IFAT), immunoperoxidase (IP), counter-electrophoresis (CEP) and enzyme linked

immunosorbent assay (ELISA) are used in the early diagnosis of this disease, but they have some disadvantages such as cross reactions with other trematodes leading to false positive results. Therefore, the reliability of these tests is not high. In recent years, sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting procedures have initiated a new era in immunodiagnosis which greatly reduced cross-reactions. Enzyme-linked immunotransfer blot analysis (EITB) or Western blotting is evaluated in some research centers and encompasses remarkable sensitivity and specificity in diagnoses of the fasciolosis. Evaluation of sandwich ELISA and Dot ELISA as an immunological assay is used for detecting *Fasciola* copro-antigen and serum antigens in infected sheep, thus presenting an experimental trial that could be of value in providing a tool that may help in immunodiagnosis of fasciolosis.

### OBJECTIVES OF IMMUNODIAGNOSIS

The objective of research in immunodiagnosis of fasciolosis is to develop rapid, cheap and technically easy tests that can be used in epidemiological surveys to evaluate the effects of various national or international schemes of control in areas where these infections are endemic. It should provide tests that have a high degree of sensitivity and that are specific for each infection, thus enabling their employment in immunodiagnosis even when few parasites are available for direct parasitological examinations. This is an important consideration in epidemiological surveys since it is recognized that in endemic areas, only a portion of the people carrying an infection may present clinical symptoms. Research in immune-assays also needs to provide tools that assess the effectiveness of chemotherapy or other curative measures, and thereby permit monitoring of treatment. Finally, it should provide tests that identify those individuals or animals that develop immunity to the infection. Such tests will be valuable in assessing the efficacy of vaccine programmes that can be expected in the future when anti-parasite vaccination becomes available.

### NEW DEVELOPMENTS ENCOURAGED

Progress in the development of RIA, ELISA and related procedures has not yet, however, been so extensive as to replace conventional techniques. The main pitfalls have been the lack of commercial pressure to develop test kits, and the lack of good reagents. The specificity and sensitivity of the immunoassay depends on the

\*Corresponding author. E-mail: irfanrauftak@yahoo.in.

**Table 1.** Immunodiagnosis: Antigen-antibody detection.

S/N	Antigen catalogue	Techniques	Agents	Sensitivity (%)	Specificity (%)	References
1.	Somatic antigen	ELISA	Sheep serum		95	Cornelissen et al. (1992)
1a.	Somatic antigen	IHA	Sheep serum		86	Cornelissen et al. (1992)
2.	Crude excretory-secretory products (ES)	ELISA	Sheep serum		95	Cornelissen et al. (1992)
2a.	Crude excretory-secretory products (ES)	IHA	Sheep serum		86	Cornelissen et al. (1992)
3	28 kDa antigen (purified from ES)	ELISA		100		Dixit et al. (2002)
3a.	28 kDa antigen (purified from ES)	Western blot		100		Dixit et al. (2002)
3b.	28 kDa antigen (purified from ES)	Dipstick-ELISA		100		Dixit et al. (2002)
4.	mAb MM3	Copro ELISA	Sheep stool sample	0.3 ng/ml of <i>F. hepatica</i> ES antigen (100% with 1 fluke )	100	Mezo et al. (2004, 2007)

technology and on the reagents used. Limitations are now set by the lack of well-defined reagents and the false positive and false negative reactions that are seen as a consequence of this. The importance of the need for improved immunodiagnostic tests to use in individual or epidemiological studies is widely recognized and reflected in the priorities established by the Special Programme on Research and Training in Tropical Diseases of the UNDP, World Bank, and WHO, as well as by the IAEA's subprogramme component on parasitic diseases. Recent advances in separation techniques, and the production of antigens and antibodies using genetic engineering and biotechnology, augur well with development of improved serodiagnostic immunoassays using radionuclide and other tracers. This development is being encouraged by both WHO and IAEA.

## TECHNIQUES USED FOR SERODIAGNOSIS OF FASCIOSIS IN SHEEP

### Immunodiagnosis: Antibody detection

Infection with *Fasciola* spp. results in a specific antibody response. These antibodies can be detected in either serum or milk (Charlier et al., 2007). Several techniques have been described for the detection of antibodies against *Fasciola* spp. infection in sheep, such as the indirect hemagglutination test (IHA) (Levieux et al., 1992),

indirect immunofluorescence assay (IFA) (Hanna and Jura, 1977), ELISA and the Western immunoblot (Hillyer and Soler de Galanes, 1988), Dot-ELISA (Shaheen et al., 1989) and Micro-ELISA (Carnevale et al., 2001).

Antibodies to *Fasciola* spp. in infected hosts can be detected by ELISA (Ab ELISA) as early as one to two weeks post-infection (Hillyer et al., 1992), while eggs of flukes are found in faeces only after 12 - 14 weeks of infection (Burger, 1992). The Ab ELISAs have sensitivities and specificities of 87-100 and 86-100%, respectively. However, cross-reactions were seen with serum samples obtained from patients with hydatidosis and toxocariasis (Rokni et al., 2004) when using crude excretory secretory products (ES) of adult worms as the antigen. To improve the sensitivity and specificity of Ab ELISA, antigens purified from crude ES of flukes, recombinant antigens, or synthetic protein antigens should be used (Cornelissen et al., 2001; Silva et al., 2004; Yokanath et al., 2005) (Table 1).

### Immunodiagnosis: Antigen detection

Active infection by *Fasciola* spp. can be demonstrated by the detection of metabolic products of flukes in the circulation. Such a test can also be used to confirm the efficacy of chemotherapy. Several assays have been developed to detect *Fasciola* spp. antigen in serum and faeces using monoclonal antibodies (Espino et al., 1994; Fagbemi et al., 1997; Mezo et al., 2004).

The antigen in blood can be detected by ELISA from one week post-infection onwards. However, Ag-ELISA has not been further developed because antigenaemia only develops when immature flukes are actively migrating through the liver parenchyma during 1-3 weeks post-infection and circulating antigens cannot be detected anymore once the flukes are established and mature to adult worms (Langley and Hillyer, 1989).

Copro Ag-ELISA has been applied to detect ES productions of *Fasciola* in stool samples by using monoclonal antibodies. The antigen can be detected as early as 3-4 weeks post-infection when the flukes reside in the host liver (Fagbenmi et al., 1997). In addition, a strong correlation between copro-antigen levels and the numbers of flukes was seen (Abdel-Rahman et al., 1998). Circulating antigens were detected in 100% of sheep with 1 fluke and in 100% of cattle with 2 flukes, from five weeks post-infection (wpi) onwards (Mezo et al., 2004). The copro-antigen became undetectable from 1 - 3 weeks after treatment with a flukicide in sheep and cattle (Mezo et al., 2004) and from 2 months post-treatment in 78.6% of patients (Espino et al., 1994). The copro Ag-ELISA was demonstrated to have a sensitivity and specificity close to 100% (Table 1).

## CONCLUSIONS

Although, coprological techniques based on the demonstration of eggs in faeces of the definitive host can be seen as a "gold-standard", these techniques are not always adequate, especially for diagnosis of human fasciolosis, because during the long prepatent period immature flukes do not lay eggs, and in the case of ectopic migration of flukes, "false" positive results were seen in some cases of humans following eating from bovine livers harboring fluke eggs (Hillyer, 1999). Immunological techniques provide the advantage of being applicable during all stages of the liver fluke lifecycle. These are reliable detection approaches, especially during the invasive or acute phases.

In spite of that, parasitological and immunological techniques are useful tools in epidemiological studies to estimate the prevalence and to map the presence of human and animal fasciolosis (Hillyer, 1999). Several serological techniques have also proved to be excellent methods for monitoring post-treatment evolution (Mas-Coma et al., 2005). The need to find and establish a new sensitive and specific method and to decrease as much as possible the cases of cross-reactions made us to evaluate the EITB test in this regard.

Despite the numerous above-mentioned assays, the serodiagnosis of naturally acquired fasciolosis in ruminants-in contrast to experimental infections is not yet entirely satisfactory and often rather limited. Recent research efforts have concentrated on the isolation of *F. hepatica* antigens by elution from polyacrylamide gels and on the isolation and translation of messenger RNA

from adult *F. hepatica*.

Future investigations will show whether continued development of *F. hepatica* antigens by molecular biology techniques can lead to an improved, widely applicable and economical assay for the serodiagnosis of naturally acquired fasciolosis.

## Conflict of Interests

The author(s) have not declared any conflict of interests.

## REFERENCES

- Abdel-Rahman EH, Abdel Mageed KN (2000). Molecular identity of major cross-reactive adult antigens in *Fasciola gigantica*, *Toxocara vitulorum* and *Moniezia expansa*. *J. Egypt. Soc. Parasitol.* 30:561-571.
- Abdel-Rahman SM, O'Reilly KL, Malone JB (1998). Evaluation of diagnostic monoclonal antibody based capture enzyme-linked immunosorbent assay for detection of a 26 to 28 kd *Fasciola hepatica* coproantigen in cattle. *Am. J. Vet. Res.* 59:533-537.
- Allan JC, Valasquez-Tohom, Torres- Alvarez R, Yarrita P, and Garcia-Noval J (1996). Filed trial of the Coproantigen-based diagnosis of *Taenia solium* taeniasis by enzyme-linked immunosorbent assay. *Am. J. Trop. Med. Hyg.* 54:352-356.
- Burger HJ (1992). Helminthn, In: *Veterinarmedizinische Parasitologie*, Korting, W. (Ed.) 4<sup>th</sup> (Ed.: Parey V.P.), Berlin: 174.
- Carnevale S, Rodriguez MI, Santillan G, Labbe JH, Cabrera MG, Bellegarde EJ, Velasquez JN, Trgovcic JE, Guarnera EA (2001). Immunodiagnosis of human fascioliasis by an enzyme-linked immunosorbent assay (ELISA) and a Micro-ELISA. *Clin. Diagn. Lab. Immunol.* 8:174-177.
- Charlier J, Duchateau L, Claerebout E, Williams D, Vercruysse J (2007). Association between anti-*Fasciola hepatica* antibody levels in bulk-tank milk samples and production parameters in dairy herds. *Prev. Vet. Med.* 78:57-66.
- Charmy RA, El-Kashef HS, ElGhorab NM, Gad HSM (1997). Identification of surface tegumental antigens of normal and irradiated schistosomula. *J. Egypt. Soc. Parasitol.* 27:479-491.
- Cornelissen JB, De Leeuw WA, Vander Heijden PJ (1992). Comparison of and indirect haemagglutination assay and an ELISA for diagnosing *Fasciola hepatica* in experimentally and naturally infected sheep. *Vet. Q.* 14:152-156.
- Cornelissen JB, Gaasenbeek CP, Borgsteede FH, Holland WG, Harmsen MM, Boersema WJ (2001). Early immunodiagnosis of fascioliasis in ruminants using recombinant *Fasciola hepatica* cathepsin L-like protease. *Int. J. Parasitol.* 31:728-737.
- Cornelissen JBWJ, Gaasenbeek CPH, Boersma W, Borgsteede FHM Van Milligen FJ (1999). Use of pre-selected epitope cathepsin -L1 in a highly specific peptide-based immunoassay for the diagnosis of *Fasciola hepatica* infection in cattle. *Int. J. Parasitol.* 29:685-696.
- Dixit AK, Yadav SC, Sharma RL (2002). 28 kDa *Fasciola gigantica* cysteine proteinase in the diagnosis of prepatent ovine fasciolosis. *Vet. Parasitol.* 109:233-247.
- Espino AM, Marcet R, Finlay CM (1994). Detection of circulating excretory secretory antigens in human fascioliasis by sandwich enzyme-linked immunosorbent assay. *J. Clin. Microbiol.* 28:2637-2640.
- Fagbenmi BO, Aderibigbe OA, Guobadia EE (1997). The use of monoclonal antibody for the immunodiagnosis of *Fasciola gigantica* infection in cattle. *Vet. Parasitol.* 69:231-240.
- Fagbenmi BO, Aderibigbe OA, Guobadia, EE (1999). The use of monoclonal antibody for the immunodiagnosis of *Fasciola gigantica* infection in cattle. *Vet. Parasitol.* 69:231-240.
- G'nen B, Sarimehmetolu HO, Koro M, Kiracali, F (2004). Comparison of crude and excretory/secretory antigens for the diagnosis of *Fasciola hepatica* in sheep by western blotting. *Turk. J. Vet. Anim. Sci.* 28: 943-949.

- Hammond JA, and Sewell MMH (1990). Diseases caused by Helminths. In: M. M. H. Sewell and D. W. Brocklesdy (Eds.), Handbook of Animal Diseases in the Tropics, 4th edn, (CTVM, Edinburgh University). pp. 119-123.
- Hanna RE, Jura W (1977). Antibody response of calves to a single infection of *Fasciola gigantica* determined by an indirect fluorescent antibody technique. Res. Vet. Sci. 22:339-342.
- Hillyer GM, Soler De Galanes M, Rodriguez-Perez J, Bjorland J, De Lagrava MS, Guzman SR, Bryan RT (1992). Use of the falcon assay screening test-enzyme-linked immunosorbent assay (FAST-ELISA) and the enzyme-linked immunoelectrotransfer blot (EITB) to determine the prevalence of human fascioliasis in the Bolivian Altiplano. Am. J. Trop. Med. Hyg. 46:603-609.
- Hillyer GV (1999). Immunodiagnosis of human and animal. In: Fasciolosis (Dalton J.P.ed).CABI Publishing, Wallingford, UK: 345-449.
- Hillyer GV, De Weil NS (1987) Partial purification of *Fasciola hepatica* antigen for the immunodiagnosis of fascioliasis in rats. J. Parasitol. 63:430-433.
- Hillyer GV, Soler de Galanes M (1988). Identification of a 17-kilodalton *Fasciola hepatica* immunodiagnostic antigen by enzyme-linked immunoelectrotransfer blot technique. J. Clin. Microbiol. 26:2048-2053.
- Khalil HM, Makled MKH, El-Missiry AG, Khalil NM, Sonobol SE (1989). The application of *S. mansoni* adult and soluble egg antigens for serodiagnosis of schistosomiasis by CIEB, IHA and ELISA. J. Egypt. Soc. Parasitol. 19:872-843.
- Langley RJ, Hillyer GV (1989). Detection of circulating parasitic antigen in murine fascioliasis by two-site enzyme linked immunosorbent assay. Am. J. Trop. Med. Hyg. 41:472-478.
- Levieux D, Levieux A, Mage C, Venien A (1992). Early immunodiagnosis of bovine fascioliasis using the specific antigen f2 in a passive hemagglutination test. Vet. Parasitol. 42:77-86.
- Maleewong W, Wongkhan C, Intapan PM, Pipitgool V (1999). *Fasciola gigantica* specific antigens: purification by a continuous-elusion method and its evaluation for the diagnosis of human Fascioliasis. Am. J. Trop. Med. Hyg. 61:648-651.
- Mas-Coma S, Bargues MD, Valero MA (2005). Fasciolosis and other plant-borne trematode zoonoses. Int. J. Parasitol. 35:1255-1278.
- Mezo M, González-Warleta M, Carro C, Ubeira, FM (2004). An ultrasensitivity capture ELISA for detection of *Fasciola hepatica* coproantigens in sheep and cattle using a new monoclonal antibody (MM3). J. Parasitol. 90:845-852.
- Mezo M, González-Warleta M, Ubeira FM (2007). The use of MM3 monoclonal antibodies for the early immunodiagnosis of ovine fascioliasis. J. Parasitol. 93:65-72.
- Noureldin MS, EL-Ganaini GA, Abou EL-Enin AM, Hussein EM, Sultan DM (2004). Evaluation of seven assays detecting serum immunoglobulin classes and subclasses and salivary and faecal secretory IgG against *Fasciola* excretory/secretory(ES) antigen in diagnosing Fascioliasis. J. Egypt. Soc. Parasitol. 34:691-704.
- Ozer BL, Ender SG, Yuksel G, Gurden YU, Sedat B. (2003). Endoscopic extraction of living *Fasciola hepatica*: Case report and literature review. Turk. J. Gastroenterol. 14(1):74-77
- Robinson MW, Dalton JP (2009). Zoonotic helminth infections with particular emphasis on fasciolosis and other trematodiasis. Philos. Trans. R. Soc. Lond. B Biol. Sci. 364:2763-2776
- Rokni MB, Baghernejad A, Mohebbali M, Kia EB (2004). Enzyme linked immunotransfer blot analysis of somatic and excretory-secretory antigens of *Fasciola hepatica* in diagnosis of human fascioliasis. Iran. J. Public Health 33:8-13.
- Shaheen HI, Kamal KA, Farid Z, Mansour N, Boctor FN, Woody JN (1989). Dotenzyme linked immunosorbent assay (dot-ELISA) for rapid diagnosis of human fasciolosis. J. Parasitol. 75:549-552.
- Silva E, Castro A, Lopes A, Rodrigues A, Dias C, Conceição A, Alonso J, Correia da Costa JM, Bastos M, Parra F, Moradas P, Moradas-Ferreira P and Silva M (2004). A recombinant antigen recognized by *Fasciola hepatica*-infected hosts. J. Parasitol. 90:746-751.

A detailed 3D rendering of biological structures, possibly a plant stem or a complex cellular network, with various green, blue, and purple components. The background is dark, making the glowing structures stand out.

# Biotechnology and Molecular Biology Reviews

*Related Journals Published by Academic Journals*

- *Journal of Cell and Animal Biology*
- *African Journal of Environmental Science and Technology*
- *African Journal of Biochemistry Research*
- *African Journal of Agricultural Research*
- *African Journal of Microbiology Research*
- *African Journal of Biotechnology*
- *African Journal of Pharmacy and Pharmacology*
- *Scientific Research and Essays*

**academic**Journals